Compare · CLOV vs ILMN
CLOV vs ILMN
Side-by-side comparison of Clover Health Investments Corp. (CLOV) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CLOV and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $28.24B, about 11.6x CLOV ($2.43B).
- Over the past year, CLOV is up 57.2% and ILMN is up 94.2% - ILMN leads by 37.0 points.
- CLOV has been more active in the news (12 items in the past 4 weeks vs 11 for ILMN).
- ILMN has more recent analyst coverage (25 ratings vs 12 for CLOV).
- Company
- Clover Health Investments Corp.
- Illumina Inc.
- Price
- $4.62+4.89%
- $186.76-1.85%
- Market cap
- $2.43B
- $28.24B
- 1M return
- -6.77%
- +13.80%
- 1Y return
- +57.24%
- +94.24%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2000
- News (4w)
- 12
- 11
- Recent ratings
- 12
- 25
Clover Health Investments Corp.
Clover Health Investments, Corp. operates as a Medicare Advantage insurer in the United States. The company through its software platform provides preferred provider organization and health maintenance organization health plans for Medicare-eligible consumers. Clover Health Investments, Corp. was founded in 2014 and is headquartered in Franklin, Tennessee.
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest CLOV
- CEO, Medicare Advantage Reynoso Jamie L. sold $21,921 worth of shares (4,839 units at $4.53) as part of a pre-agreed trading plan, decreasing direct ownership by 0.17% to 2,814,640 units (SEC Form 4)
- Clover Health Investments Corp. filed SEC Form 8-K: Other Events
- Chief Executive Officer Toy Andrew sold $292,860 worth of shares (62,711 units at $4.67), decreasing direct ownership by 0.65% to 9,547,114 units (SEC Form 4) (tax withholding)
- CEO, Counterpart Health Wai Conrad sold $113,084 worth of shares (24,215 units at $4.67), decreasing direct ownership by 2% to 1,145,699 units (SEC Form 4) to satisfy withholding tax
- CEO, Medicare Advantage Reynoso Jamie L. sold $61,266 worth of shares (13,119 units at $4.67), decreasing direct ownership by 0.46% to 2,819,479 units (SEC Form 4) (tax withholding)
- Chief Legal Officer Soares Karen sold $49,124 worth of shares (10,519 units at $4.67), decreasing direct ownership by 0.67% to 1,557,222 units (SEC Form 4) to cover taxes
- Interim CFO Thornton Joseph Clay sold $21,622 worth of shares (4,630 units at $4.67), decreasing direct ownership by 0.38% to 1,212,954 units (SEC Form 4) (for withholding tax)
- CEO, Medicare Advantage Reynoso Jamie L. sold $11,157 worth of shares (2,384 units at $4.68) as part of a pre-agreed trading plan, decreasing direct ownership by 0.08% to 2,832,598 units (SEC Form 4)
- Clover Health to Report Second Quarter 2026 Financial Results on August 5, 2026
- Clinical Excellence in Continuity of Care: Counterpart Assistant (CA) Use Associated With Stronger Performance Across Transitions of Care Measures and Post-Hospitalization Follow-Up
Latest ILMN
- Illumina expands Billion Cell Atlas program with new AI drug developers
- Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
- Illumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer
- Director Meister Keith A. was granted 142 shares, increasing direct ownership by 2% to 6,780 units (SEC Form 4)
- Director Ullem Scott B. was granted 167 shares, increasing direct ownership by 2% to 11,030 units (SEC Form 4)
- Bernstein resumed coverage on Illumina with a new price target
- Chief Legal Officer Davies Scott M sold $110,700 worth of shares (615 units at $180.00), decreasing direct ownership by 3% to 20,953 units (SEC Form 4)
- Director Skovronsky Daniel was granted 1,674 shares (SEC Form 4)
- SEC Form 3 filed by new insider Skovronsky Daniel
- Illumina Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits